Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Nkarta, Inc. (NKTX)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 48,660,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Nkarta is a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Co. has two product candidates, NKX101 and NKX019. Both product candidates were generated using Co.'s NK cell engineering platform. NKX101 is designed to improve the power of innate NK biology to detect and kill cancerous cells. NKX019 is based on the ability to treat a variety of B-cell malignancies by targeting the CD19 antigen that is found on these types of cancerous cells, where CD19-targeted engineered NK cells, T cells and monoclonal antibodies have demonstrated clinical activity.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 5,000,000 5,000,000 5,000,000 5,000,000
Total Buy Value $50,000,000 $50,000,000 $50,000,000 $50,000,000
Total People Bought 2 2 2 2
Total Buy Transactions 2 2 2 2
Total Shares Sold 12,510 37,385 42,746 138,518
Total Sell Value $154,387 $371,794 $393,775 $1,753,059
Total People Sold 2 5 6 6
Total Sell Transactions 2 7 14 32
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 127
  Page 4 of 6  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Brandenberger Ralph See Remarks   •       –      –    2021-09-01 4 AS $32.08 $132,811 D/D (4,140) 0     -
   Brandenberger Ralph See Remarks   •       –      –    2021-09-01 4 OE $0.41 $15,278 D/D 4,140 4,140     -
   Rajangam Kanya Chief Medical Officer   •       –      –    2021-08-05 4 AS $37.28 $372,800 D/D (10,000) 0     -
   Rajangam Kanya Chief Medical Officer   •       –      –    2021-08-05 4 OE $0.41 $4,100 D/D 10,000 10,000     -
   Trager James Chief Scientific Officer   •       –      –    2021-08-02 4 AS $31.53 $113,508 D/D (3,600) 44,372     -
   Trager James Chief Scientific Officer   •       –      –    2021-08-02 4 OE $3.89 $8,753 D/D 2,250 47,972     -
   Mahmood Nadir See Remarks   •       –      –    2021-07-01 4 AS $31.71 $206,115 D/D (6,500) 27,288     -
   Mahmood Nadir See Remarks   •       –      –    2021-07-01 4 OE $3.89 $13,615 D/D 3,500 33,788     -
   Hastings Paul J Chief Executive Officer   •       •      –    2021-06-21 4 AS $26.39 $226,219 D/D (8,500) 227,561     -
   Mahmood Nadir See Remarks   •       –      –    2021-06-16 4 OE $3.89 $7,002 D/D 1,800 30,288     -
   Brandenberger Ralph See Remarks   •       –      –    2021-06-02 4 AS $24.50 $101,430 D/D (4,140) 0     -
   Brandenberger Ralph See Remarks   •       –      –    2021-06-02 4 OE $0.41 $15,278 D/D 4,140 4,140     -
   Mahmood Nadir See Remarks   •       –      –    2021-05-10 4 AS $27.16 $81,480 D/D (3,000) 28,488     -
   Trager James Chief Scientific Officer   •       –      –    2021-05-03 4 AS $31.64 $113,904 D/D (3,600) 45,722     -
   Trager James Chief Scientific Officer   •       –      –    2021-05-03 4 OE $3.89 $8,753 D/D 2,250 47,972     -
   Mahmood Nadir See Remarks   •       –      –    2021-04-01 4 AS $32.70 $114,450 D/D (3,500) 31,488     -
   Mahmood Nadir See Remarks   •       –      –    2021-04-01 4 OE $3.89 $13,615 D/D 3,500 34,988     -
   Hastings Paul J Chief Executive Officer   •       •      –    2021-03-30 4 AS $30.23 $522,540 D/D (17,000) 236,061     -
   Trager James Chief Scientific Officer   •       –      –    2021-02-02 4 AS $40.00 $112,000 D/D (2,800) 47,072     -
   Trager James Chief Scientific Officer   •       –      –    2021-02-02 4 OE $18.00 $50,400 D/D 2,800 49,872     -
   Trager James Chief Scientific Officer   •       –      –    2021-02-01 4 AS $38.07 $139,229 D/D (3,600) 47,072     -
   Trager James Chief Scientific Officer   •       –      –    2021-02-01 4 OE $3.89 $8,753 D/D 2,250 50,672     -
   Mahmood Nadir See Remarks   •       –      –    2021-01-25 4 AS $48.40 $267,120 D/D (5,500) 31,488     -
   Mahmood Nadir See Remarks   •       –      –    2021-01-25 4 OE $3.89 $21,395 D/D 5,500 36,988     -
   Mahmood Nadir See Remarks   •       –      –    2021-01-14 4 OE $3.89 $11,993 D/D 3,083 31,488     -

  127 Records found
  1  2  3  4  5  6   
  Page 4 of 6
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed